您好,欢迎来到科研在线!科研采购 · 选型 · 实验方法
首页产品库品牌馆产品类别品牌新闻会议会展产品试用求职招聘资讯专题教程
PRO / Antibodies

FITC Anti-Human CD22 Antibody

FITC Anti-Human CD22 Antibody

英诺赛图(InnoCyto)的 FITC Anti-Human CD22 Antibody(克隆 HIB22) 为鼠源 IgG1 单克隆抗体,靶向 CD22(别名 BL-CAM 等),FITC 标记(488 nm 蓝色激光激发),适用于流式细胞术。提供 25 tests、100 tests 规格,目录价 ¥949 起,仅供科研使用(RUO)。

生物试剂 供应商 上海英诺赛图 ↗ 型号 100607 更新 2026-11-12
参考价格区间
¥949
含税参考价,实际以配置与渠道报价为准
本条目供应商 上海英诺赛图原厂 1865个条目 进入企业主页

01产品图片

02产品简介

英诺赛图(InnoCyto)的 FITC Anti-Human CD22 Antibody(克隆 HIB22) 为鼠源 IgG1 单克隆抗体,靶向 CD22(别名 BL-CAM 等),FITC 标记(488 nm 蓝色激光激发),适用于流式细胞术。提供 25 tests、100 tests 规格,目录价 ¥949 起,仅供科研使用(RUO)。

03产品介绍

规格与货号

100607 | 25 tests | ¥949

100608 | 100 tests | ¥2,373

Product Details

Regulatory Status|RUO

Protein Concentration|Supplied at a lot-specific concentration.

Storage&Handling|The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Recommended Usage|For flow cytometric staining, it is recommended to use 5 µL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. FITC has an excitation max at 493 nm and an emission max at 525 nm.

See All Formats|Clone HIB22

Background Information

CD22 is a B cell–specific transmembrane glycoprotein that functions as an important regulator of B cell receptor (BCR) signaling and immune tolerance. Also known as Siglec-2, CD22 belongs to the sialic acid–binding immunoglobulin-like lectin (Siglec) family and is expressed almost exclusively on mature B cells, with expression increasing as B cells progress from the naïve to mature stages. Through its inhibitory signaling capacity, CD22 helps fine-tune B cell activation and prevent inappropriate immune responses.

Structurally, CD22 is a type I transmembrane protein with a large extracellular region composed of seven immunoglobulin-like domains. The N-terminal domain mediates binding to sialic acid–containing glycans, which serve as its primary ligands. CD22 preferentially recognizes α2,6-linked sialic acids that are commonly present on glycoproteins and glycolipids expressed on B cells themselves (cis interactions) as well as on neighboring cells (trans interactions). The cytoplasmic tail of CD22 contains multiple immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which are essential for its signaling function. Functionally, CD22 acts as a negative regulator of BCR signaling. Upon BCR engagement, CD22 becomes phosphorylated and recruits phosphatases such as SHP-1 to its ITIM motifs. These phosphatases attenuate downstream signaling pathways, thereby raising the threshold for B cell activation. Through this mechanism, CD22 contributes to the maintenance of B cell tolerance and limits excessive antibody production. CD22 also influences B cell survival, migration, and interactions within lymphoid tissues.

Dysregulation of CD22 expression or signaling has been linked to immune-mediated diseases and malignancy. Reduced CD22 function can lead to hyperactive B cells and has been associated with autoimmune diseases such as systemic lupus erythematosus. In contrast, CD22 is frequently overexpressed on B cell malignancies, including B cell acute lymphoblastic leukemia (B-ALL) and certain non-Hodgkin lymphomas, making it an attractive diagnostic and therapeutic target.

CD22 plays a significant role in therapeutics, particularly in the treatment of B cell cancers. Antibody-based therapies targeting CD22 have been developed to selectively eliminate malignant B cells. Notably, antibody–drug conjugates and immunotoxins that bind CD22 deliver cytotoxic agents directly to cancerous B cells, sparing most non–B cell populations. CD22 is also being explored as a target for engineered cell therapies and for strategies aimed at modulating B cell activity in autoimmune disease. Together, these approaches highlight CD22 as a key molecule at the intersection of B cell biology, disease, and targeted therapy.

Data Sheets

Human peripheral blood lymphocytes stained either FITC Anti-Human CD22 clone HIB22 (color-filled histogram) or an isotype control (gray histogram).

04完整参数表

参数由厂商资料整理,采购前请以最终报价单与技术协议为准。

包装规格25 tests
CloneHIB22
ApplicationFlow Cytometry
ReactivityHuman
FormatFITC
Target NameCD22, BL-CAM, Siglec-2
IsotypeMouse IgG1
Antibody TypeMonoclonal
Regulatory StatusRUO
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein ConcentrationSupplied at a lot-specific concentration.
Excitation LaserBlue Laser (488 nm)
RRIDAB_3738580
目录价¥949

05荣誉与资质

该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。

  • 营业执照未上传
  • 品牌授权未上传
  • 产品检测报告未上传
会员身份
收费会员
经营身份
原厂
成立年份
2020 年
所在地
上海
收录条目
1865 个
平台核验
平台代管
向品牌方索取资质文件

06品牌与供应商

上海英诺赛图 原厂
InnoCyto

以可信赖的细胞研究试剂,助力科研突破

进入企业主页
1865 本目录条目
产地 / 总部上海市浦东新区
成立年份2020 年
本目录主营生化试剂 / 蛋白与抗体

InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。

售后与服务

品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。

引用此条目 产品目录 · 更新于 2026-11-12
科研在线(TeleVM). FITC Anti-Human CD22 Antibody(100607)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/fitc-anti-human-cd22-antibody.html.
TeleVM. (2026, November 12). FITC Anti-Human CD22 Antibody(100607). 产品目录. https://www.suprotek.cn/products/item/fitc-anti-human-cd22-antibody.html
@misc{biocsp_item_fitc_anti_human_cd22_antibody,
  title        = {FITC Anti-Human CD22 Antibody(100607)},
  author       = {{科研在线}},
  year         = {2026},
  howpublished = {产品目录},
  note         = {更新于 2026-11-12,产品目录},
  url          = {https://www.suprotek.cn/products/item/fitc-anti-human-cd22-antibody.html}
}

GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。

许可:CC BY-NC 4.0 · 转载注明来源
获取正式报价

FITC Anti-Human CD22 Antibody

提交后由平台转给品牌方,通常 1 个工作日内联系。不需要注册。